Cel Sci Corp (CVM) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Cel Sci reported revenue of $0. Net income was -$25.4M, or -$6.27 per diluted share. Operating activities generated -$17.1M of cash, leaving -$17.2M of free cash flow. At fiscal year end, Cel Sci held $28.2M in total assets against $12.2M in total liabilities.
Open the full interactive Cel Sci financials → Quarterly statements, key ratios, valuation history and price charts.
Cel Sci Key Stats
| Share Price | $1.75 |
|---|---|
| Market Cap | $21.2M |
| 52-Week Range | $0.97 – $10.11 |
| Shares Outstanding | 1.4 million (basic, 2023 Q1) |
Cel Sci Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$29.0M | -$36.2M | -$36.1M | -$31.5M | -$26.4M | -$24.8M |
| Pre-Tax Income | -$30.3M | -$36.4M | -$36.7M | -$32.2M | -$27.6M | -$25.4M |
| Net Income | -$30.3M | -$36.4M | -$36.7M | -$32.2M | -$27.6M | -$25.4M |
| Diluted EPS | -$24.60 | -$27.90 | -$26.10 | — | -$15.30 | -$6.27 |
Cel Sci Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$6.1M | -$5.5M | -$5.5M | -$5.7M |
| Diluted EPS | -$1.50 | -$0.68 | -$0.67 | -$0.47 |
Cel Sci Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.5M | $36.1M | $22.7M | — | — | — |
| Current Assets | $17.7M | $45.3M | $25.4M | $6.9M | $6.1M | $11.6M |
| Total Assets | $40.5M | $75.9M | $50.5M | $30.5M | $27.0M | $28.2M |
| Current Liabilities | $4.3M | $3.9M | $4.7M | $5.6M | $4.6M | $5.1M |
| Total Long-Term Debt | — | — | — | — | — | $8.0M |
| Total Liabilities | $20.8M | $19.3M | $18.4M | $17.3M | $14.1M | $12.2M |
| Shareholders' Equity | $19.7M | $56.5M | $32.2M | $13.2M | $12.9M | $16.0M |
Cel Sci Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$15.3M | -$18.8M | -$18.2M | -$22.8M | -$18.8M | -$17.1M |
| Cash From Investing | -$2.7M | -$15.2M | $5.5M | -$372,262 | -$108,086 | -$38,109 |
| Cash From Financing | $25.0M | $54.5M | -$638,426 | $4.7M | $19.5M | $23.4M |
| Free Cash Flow | -$12.6M | -$27.8M | -$18.9M | -$23.2M | -$18.9M | -$17.2M |
Figures from Cel Sci's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cel Sci financials page for every line item.
Cel Sci Company Profile
| Ticker | CVM |
|---|---|
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Vienna, Virginia |
| Incorporated in | Colorado |
| Fiscal Year End | September 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000725363 |
Frequently Asked Questions
What was Cel Sci's revenue in fiscal 2025?
Cel Sci (CVM) reported revenue of $0 for fiscal 2025.
What is Cel Sci's annual revenue history?
Cel Sci's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Cel Sci's net income in fiscal 2025?
Cel Sci reported net income of -$25.4M for fiscal 2025.
What was Cel Sci's earnings per share (EPS) in fiscal 2025?
Cel Sci's diluted EPS was -$6.27 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cel Sci generate in fiscal 2025?
Cel Sci generated -$17.2M of free cash flow in fiscal 2025.
What was Cel Sci's revenue last quarter?
In its most recent reported quarter (2026 Q3), Cel Sci reported revenue of $0.
How much debt does Cel Sci have?
Cel Sci reported $8.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Cel Sci are outstanding?
Cel Sci reported a weighted average of 1.4 million basic shares outstanding in 2023 Q1.
What is Cel Sci's market cap?
Based on its latest closing price, Cel Sci (CVM) has a market capitalization of about $21.2M.
When does Cel Sci's fiscal year end?
Cel Sci's fiscal year end, as registered with the SEC, is September 30.
Where is Cel Sci headquartered?
Cel Sci lists its business address in Vienna, Virginia in its SEC filings.
Cel Sci Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →